Technical Analysis for GALT - Galectin Therapeutics Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| MACD Bearish Centerline Cross | Bearish | 3.27% | |
| Crossed Above 50 DMA | Bullish | 3.27% | |
| Outside Day | Range Expansion | 3.27% | |
| Lower Bollinger Band Touch | Weakness | 3.27% | |
| Fell Below 50 DMA | Bearish | 11.27% | |
| 180 Bearish Setup | Bearish Swing Setup | 11.27% | |
| Stochastic Reached Oversold | Weakness | 11.27% | |
| Earnings Movers | Other | 11.27% | |
| Below Lower BB | Weakness | 11.27% | |
| Lower Bollinger Band Touch | Weakness | 11.27% |
| Alert | Time |
|---|---|
| Possible NR7 | 4 minutes ago |
| Up 3% | about 1 hour ago |
| 60 Minute Opening Range Breakout | about 2 hours ago |
| Rose Above Previous Day's High | about 4 hours ago |
| Up 2% | about 4 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/13/2024
Galectin Therapeutics Inc., a development stage company, engages in the development of therapies for cancer and fibrotic disease. Its lead product candidates include GR-MD-02, a complex polysaccharide polymer for the treatment of liver fibrosis and fatty liver disease for which the company intends to initiate a Phase I clinical trial in patients with non-alcoholic steatohepatitis; and GM-CT-01, a linear polysaccharide polymer comprising mannose and galactose that is in a Phase I/II clinical trial in Europe as a combination therapy with a tumor vaccine in patients with advanced melanoma. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Cancer Alcohol Tumor Melanoma Hepatitis Steatohepatitis Non Alcoholic Fatty Liver Disease Liver Disease Therapies For Cancer Fibrotic Disease Lectins Liver Fibrosis Galectin Lactose Combination Therapy Fatty Liver Fatty Liver Disease Galectin 3 Galecto Biotech
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Cancer Alcohol Tumor Melanoma Hepatitis Steatohepatitis Non Alcoholic Fatty Liver Disease Liver Disease Therapies For Cancer Fibrotic Disease Lectins Liver Fibrosis Galectin Lactose Combination Therapy Fatty Liver Fatty Liver Disease Galectin 3 Galecto Biotech
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 4.2684 |
| 52 Week Low | 1.28 |
| Average Volume | 207,741 |
| 200-Day Moving Average | 2.10 |
| 50-Day Moving Average | 2.96 |
| 20-Day Moving Average | 3.30 |
| 10-Day Moving Average | 3.20 |
| Average True Range | 0.30 |
| RSI (14) | 46.24 |
| ADX | 26.43 |
| +DI | 12.08 |
| -DI | 21.10 |
| Chandelier Exit (Long, 3 ATRs) | 2.98 |
| Chandelier Exit (Short, 3 ATRs) | 3.64 |
| Upper Bollinger Bands | 3.69 |
| Lower Bollinger Band | 2.92 |
| Percent B (%b) | 0.18 |
| BandWidth | 23.39 |
| MACD Line | -0.01 |
| MACD Signal Line | 0.08 |
| MACD Histogram | -0.089 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.57 | ||||
| Resistance 3 (R3) | 3.53 | 3.33 | 3.49 | ||
| Resistance 2 (R2) | 3.33 | 3.20 | 3.35 | 3.46 | |
| Resistance 1 (R1) | 3.19 | 3.12 | 3.26 | 3.23 | 3.43 |
| Pivot Point | 2.99 | 2.99 | 3.02 | 3.01 | 2.99 |
| Support 1 (S1) | 2.85 | 2.86 | 2.92 | 2.89 | 2.69 |
| Support 2 (S2) | 2.65 | 2.78 | 2.67 | 2.66 | |
| Support 3 (S3) | 2.51 | 2.65 | 2.64 | ||
| Support 4 (S4) | 2.55 |
